Abstract
The cost and time needed to conduct whole-genome sequencing (WGS) have decreased significantly in the last 20 years. At the same time, the number of conditions with a known molecular basis has steadily increased, as has the number of investigational new drug applications for novel gene-based therapeutics. The prospect of precision gene-targeted therapy for all seems in reach… or is it? Here we consider practical and strategic considerations that need to be addressed to establish a foundation for the early, effective, and equitable delivery of these treatments.
Original language | English (US) |
---|---|
Pages (from-to) | 7-12 |
Number of pages | 6 |
Journal | American Journal of Medical Genetics, Part C: Seminars in Medical Genetics |
Volume | 193 |
Issue number | 1 |
DOIs |
|
State | Published - Mar 2023 |
Externally published | Yes |
ASJC Scopus subject areas
- Genetics
- Genetics(clinical)